N30 Pharmaceuticals has selected Greenphire's global payment technology platforms, eClinicalGPS and ClinCard, to streamline payments to investigators and subjects throughout its Phase 1a/2b Cystic Fibrosis study commenced in the month of March.
The payment technology platforms will ensure that clinical trial payments from sponsor to site and from site to subjects are compliant with relevant regulations, including the Sunshine Act.
N30 Pharma will use the eClinicalGPS platform to automate payments to investigative sites involved in the trial.
The company will use the ClinCard platform to reimburse subjects and to arrange subject travel, thereby reducing costs and administrative complexities associated with the trial.
N30 Pharma CFO Tom Sokolowski said, "Using Greenphire's systems will ensure that our staff and investigators can focus entirely on the scientific and patient-centric elements of the study while remaining confident that payments are accurate, quick, and fully accounted for."
Greenphire CEO and Co-Founder Sam Whitaker said that the company is looking forward to collaborate with N30 Pharma on its first clinical trial in cystic fibrosis which it hopes will eventually result in new, effective treatments for the disease.
"By using Greenphire's payment platforms to manage the payment and subject travel aspects of the trial, N30 Pharma can reduce costs and risk, remain compliant with relevant regulations, and spend less time managing the logistical aspects of the study," Whitaker added.